2026-09-23 14:56:53 UTC#356445newconfirmedanalysis
GPCR stock news
GPCR stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire13 wire items
2026-09-22 17:20:27 UTC#350786duplicateconfirmednews
Viking Therapeutics shares up 26% as market views VK2735 maintenance data as company-specific
yahooimportance 0.30trust 0.60Viking Therapeutics, Inc. +0.80Eli Lilly and Company +0.10Novo Nordisk A/S -0.10+2 entities
2026-09-22 07:15:34 UTC#347019newconfirmednews
Structure Therapeutics reports 16.2% weight loss for oral GLP-1 Aleniglipron in Phase 2 trial
tradingviewimportance 0.60trust 0.60Structure Therapeutics Inc. +0.60Ray Stevens +0.50Novo Nordisk A/S -0.20+2 entities
2026-09-16 16:28:54 UTC#322117duplicateconfirmednews
GPCR Therapeutics reiterates Aleniglipron 16% weight loss data and Phase III trial progress
2026-09-16 15:39:21 UTC#321850newconfirmednews
GPCR Therapeutics reports 16% weight loss for Aleniglipron, phase III trials underway
2026-09-10 21:21:42 UTC#295331duplicateconfirmednews
GPCR updates status of oral GLP-1 and amylin clinical programs and strategic partnership efforts
2026-09-10 20:49:56 UTC#295153newconfirmednews
GPCR advances oral GLP-1 and amylin clinical programs, eyes strategic partnerships
2026-09-08 16:00:07 UTC#282160updateconfirmednews
Structure Therapeutics shares decline following clinical trial data for lead obesity drug candidate
2026-09-08 15:10:04 UTC#281778newconfirmednews
Structure Therapeutics experimental weight-loss pill shows 16% body weight reduction in clinical trial
bloombergimportance 0.60trust 0.80Structure Therapeutics Inc. +0.80Eli Lilly and Company -0.30Novo Nordisk A/S -0.30
2026-09-08 12:13:01 UTC#280569newconfirmednews
Structure Therapeutics reports positive ACCG-2671 SAD data and 72-week aleniglipron weight-loss results
tradingviewimportance 0.50trust 0.70Structure Therapeutics Inc. +0.60ACCG-2671 +0.50aleniglipron +0.50
2026-08-06 23:41:33 UTC#141359newconfirmednews
Structure Therapeutics Q2 adjusted loss of $0.49 per share misses analyst estimate of $0.40 loss
2026-08-06 20:45:51 UTC#140261newconfirmednews
Structure Therapeutics Q2 net loss widens on R&D spending; aleniglipron Phase 3 trials underway
2026-08-03 13:24:00 UTC#116977newconfirmednews
Exicure to issue 172,058 shares to GPCR Therapeutics to settle $1M clinical milestone payment
globenewswireimportance 0.30trust 0.90Exicure, Inc. -0.20GPCR Therapeutics, Inc. +0.20Burixafor 0+1 entities